Bill > S204

Introduced Session

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must report annually to the Food and Drug Administration (FDA) on any use of the drug in accordance with these provisions. The FDA shall post an annual summary report of such use on its website. The bill limits the liability of a sponsor, manufacturer, prescriber, or dispenser that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.

Committee Categories

Ron Johnson (R)*,  John Barrasso (R),  Roy Blunt (R),  John Boozman (R),  Richard Burr (R),  Shelley Moore Capito (R),  Thad Cochran (R),  Bob Corker (R),  Tom Cotton (R),  Mike Crapo (R),  Ted Cruz (R),  Steve Daines (R),  Joe Donnelly (D),  Michael Enzi (R),  Deb Fischer (R),  Jeff Flake (R),  Cory Gardner (R),  Lindsey Graham (R),  Chuck Grassley (R),  Orrin Hatch (R),  Dean Heller (R),  John Hoeven (R),  James Inhofe (R),  Johnny Isakson (R),  John Neely Kennedy (R),  Angus King (I),  James Lankford (R),  Mike Lee (R),  Joe Manchin (I),  John McCain (R),  Mitch McConnell (R),  Jerry Moran (R),  Lisa Murkowski (R),  Rand Paul (R),  David Perdue (R),  Rob Portman (R),  Jim Risch (R),  Mike Rounds (R),  Marco Rubio (R),  Ben Sasse (R),  Richard Shelby (R),  Luther Strange (R),  Dan Sullivan (R),  Thom Tillis (R),  Pat Toomey (R),  Roger Wicker (R),  Todd Young (R), 

Became Public Law No: 115-176. (on 05/30/2018)

Official Document